Accelerate drug development in NF1

Important research records are trapped in hospitals across the country. As a result, drug and gene therapy researchers can’t access the information they need to advance treatments.

But as a patient, you can. Unlock your records and contribute them to research, privately and securely.

RDMD

Questions? Check out our FAQ

 10053
Share:
By joining the NF1 program, you will help advance new research. If you know other patients or families who may be interested, you can help by sharing this link.
Neo.life
Neo.life
Mens Health Magazine
Mens Health Magazine
Village Global
Village Global
Xconomy
Xconomy
Techcrunch
Techcrunch
CNBC
CNBC
LUX
LUX

Why join the NF1 program

For the future

For the future

Help researchers get the information they need to advance development of new drug and gene therapies.

For the NF1 community

For the NF1 community

Jumpstart research and increase knowledge and understanding of NF1.

For you

For you

See all your records in one place. Track how you are contributing to research and be notified about new clinical trials.

How it works

Sign up

1. Sign up

Create your private account and review our research consent (takes about 10 minutes)

We get to work

2. We get to work

We do all the behind-the-scenes work to retrieve and process your records

Empower research

3. Empower research

Track your contribution to research projects and, based on your records, find out if you qualify for new clinical trials based on your records

Be part of research

Questions? Check out our FAQ

Our values &
principles.

1
Patients own their data

We believe that the only way to keep data accessible to the researchers who need it is by enabling patients to own and control their own data. Patients decide for themselves whether they want to privately and securely contribute to research, rather than having the decision made on their behalf.

2
We protect patient privacy

We abide by a strict research consent and privacy policy. We only share de-identified data with researchers, foundations, and therapeutic companies with patients’ consent. Protecting the privacy of patients and ensuring the security of their information is our highest priority.

3
Researchers gain access

We aim to make useful data accessible to all researchers who have legitimate research questions or research programs. For academic research, we offer access without charge. We take research ethics seriously, and we have policies in place to ensure that research is conducted with integrity.

4
Inclusiveness in the community

We don’t like to take sides—we give all members of the community the option to get involved. Success in rare disease research takes a village and we always welcome additional collaborators who can advance and benefit from the mission.

5
Driving forward therapeutic development

Our primary mission is to accelerate drug development, so we prioritize generating insights specifically relevant to therapeutic research. We invest deeply in quality, security, and compliance to make this a reality.

Who’s involved?

Kaleb Yohay - NYU Langone
Kaleb Yohay - NYU Langone
Children’s Tumor Foundation
Children’s Tumor Foundation

Our work with NF1 research

RDMD drives research on your condition as well as research on general health and wellness. These are the current research projects we aim to complete in order to increase our understanding of neurofibromatosis type 1 and drive drug development and clinical trials.

  • Jumpstart
  • Accelerate
  • Insights

The NF1 program is in the accelerate stage. When 100 patients join, we’ll reach our first significant research milestone.

Be part of research

Diagnostic journey

Learn how NF1 patients are typically diagnosed

  

Literature Review

Understand what evidence has been used to decide whether NF1 trials have been successful

 

Standard of care

Learn about the most common treatments used for NF1

    

Natural history

Examine in detail how NF1 progresses over time

    

Hackathon and discovery

Use the genetic information from NF1 patients to help develop new treatments